Madrigal’s Rezdiffra Brings In $14.6m During Its First Quarter
Share Price Declines On Various Concerns
Executive Summary
The first approved NASH drug topped revenue expectations during its initial quarter on the market, but Madrigal’s share price declined by 12%.